Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

EAST HANOVER, N.J., March 19, 2012 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta™ Neohaler™ (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

Arcapta Neohaler is indicated for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler is not indicated to treat asthma. It is also not indicated to treat acute deteriorations of COPD and should not be used as a rescue medication for acute symptoms.

Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist (LABA) approved in the US for maintenance treatment of airflow obstruction in patients with COPD. Arcapta Neohaler is an inhaled, steroid-free COPD treatment.

Arcapta Neohaler 75 mcg was studied in a total of 641 COPD patients in two key Phase III trials lasting 12 weeks. The primary endpoint results at week 12 showed that Arcapta Neohaler significantly improved lung function (FEV1) at 24 hours compared to placebo. As a secondary endpoint, lung function (FEV1) improvements were seen at five minutes after the first dose compared to placebo, and improvements observed at week 4 were consistently maintained over the course of 12 weeks in both trials.

"Arcapta Neohaler represents an important new treatment option for the 14 million Americans living with COPD," said Andre Wyss, President, Novartis Pharmaceuticals Corporation. "The launch of Arcapta Neohaler is a significant milestone as we continue to establish a strong respiratory presence in the US market."

COPD is a common, preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways of the lungs to noxious particles or gases. More than 14 millio
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  4WEB Medical announces the formal launch of ... osteotomy implants on the market today at this ... in Chicago .  The Osteotomy Truss ... needs with 74 size options included in one versatile ... only 15 to 18 implant sizes, which limited a ...
(Date:9/19/2014)... STATION, N.J. , Sept. 19, 2014 Merck (NYSE: ... United States and Canada , is ... Desafiando La Diabetes: Logra Tus Metas , an educational program ... their blood sugar -- a key treatment goal to help reduce ... United States are at a higher risk for developing ...
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5David Dreyer Appointed to Diplomat Board of Directors 2
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... PR News at the Platinum PR and Top Places ... Hyatt in New York City. Camino received honorable mentions ... Shoestring Campaign” — for its work elevating Latina voices ... this incredible organization and be a part of its ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Although there is ... benefits, most middle-aged and older adults in the ... exercise, according to new research. Less than ... recommendations set by the Department of Health and ... is essential for promoting health and fitness and ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... --- Domestic violence occurs at least as frequently, ... compared to opposite-sex couples, according to a review ... , Previous studies, when analyzed together, indicate that ... of lesbian, gay and bisexual individuals. However, a ... paints an incomplete picture of the true landscape, ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Domestic violence likely more frequent for same-sex couples 2
... NEW ORLEANS, LA (November 15, 2010) � Following ... Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in ... (AAPS) Annual Meeting and Exposition, President Danny D. ... awards commemorating their contributions to the pharmaceutical sciences: ...
... HealthDay Reporter , MONDAY, Nov. 15 (HealthDay News) -- Although ... death rates in public places such as restaurants, malls and ... the risk of death when used in hospitals, a new ... the type of heart rhythms associated with the heart attack, ...
... is widely believed to be caused by the gradual accumulation in ... Amyloid beta peptide is formed from a protein known as APP, ... a key area of study for the disease does not ... published in the Journal of Biological Chemistry , show that ...
... By Amanda Gardner HealthDay Reporter , SUNDAY, Nov. ... St. Paul saw a sharp decline in the number of ... elsewhere in the United States, experts say. The decline ... choosing to smoke in the first place, according to research ...
... salt each day as a teenager could reduce high ... to research presented at the American Heart Association,s Scientific ... projected the nationwide health effects of a 3-gram reduction ... boys and girls. Teenagers eat more salt each day ...
... Nov. 14 (HealthDay News) -- New research suggests that vitamin ... patients, even though it appears to double the risk for ... given that prior research has revealed that blacks are overall ... experience a stroke, compared with white patients. Blacks also have ...
Cached Medicine News:Health News:AAPS presents awards to exemplary researchers 2Health News:AAPS presents awards to exemplary researchers 3Health News:AAPS presents awards to exemplary researchers 4Health News:External Defibrillators Not Much Help in Hospitals 2Health News:External Defibrillators Not Much Help in Hospitals 3Health News:'Magic number' 695 opens up new areas for Alzheimer's research 2Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 2Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 3Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 4Health News:Less salt in teenagers' diet may improve heart health in adulthood 2Health News:Vitamin D Shortage Not Tied to Stroke Deaths in Blacks: Study 2
Poppen-Gelpi Laminectomy Retractor, self-retaining....
Valin Hemilaminectomy Retractor, self retaining with rack and pinion action....
Scoville-Haverfield Hemilaminectomy Retractor...
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment....
Medicine Products: